Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (AVDL) Stock Overview

Explore Avadel Pharmaceuticals plc’s financial performance, market position, analyst ratings, and future outlook.

AVDL●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$21.64
$0.00(0.00%)
U.S. Market is Open · 13:57

Avadel Pharmaceuticals plc (AVDL)

Meyka AI Score

Z

Key Financials

Market Cap2.1B
P/E Ratio431.08
EPS (TTM)$-0.02
ROE0.05%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$18.59

AVDL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Avadel Pharmaceuticals plc (NASDAQ: AVDL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Avadel Pharmaceuticals plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of AVDL on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $18.59 for the NASDAQ listing.

Key metrics behind Avadel Pharmaceuticals plc's NASDAQ-traded stock include a P/E ratio of 431.08 and a market capitalization of 2.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of AVDL on the NASDAQ.

Price Performance (NASDAQ: AVDL)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
1.03%
6-Month Change
42.46%
Year-to-Date (YTD) Change
0.56%
1-Year Change
144.80%
3-Year Change
135.73%
5-Year Change
114.90%
All-Time (Max) Change
84.17%

Contact Information

https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc
353 1 901 5201
10 Earlsfort Terrace, Dublin, NaN, 2

Company Facts

1,880 Employees
IPO DateJun 7, 1996
CountryIE

Frequently Asked Questions